Cover Story

Fibroblast growth factor 21 (FGF21) is a recently discovered hormone primarily produced by the liver and adipose tissue which has pleiotropic actions on glucose and lipid homeostasis. In humans, circulating levels of FGF21 are elevated in association with obesity, insulin resistance, hypertriglyceridemia, nonalcoholic fatty liver disease and type 2 diabetes. To date, no stimulus has been identified that can acutely increase serum FGF21 in either humans or animals on the time-scale of minutes to a few hours.

This study demonstrates for the first time that circulating FGF21 levels respond acutely to a dietary challenge - the ingestion of a fructose load. Moreover, the authors show that baseline levels of FGF21 are elevated in subjects with features of metabolic disease and that, in this state, the FGF21 response to fructose ingestion is further enhanced.

Full Text
The 60 Second Metabolist
In this section authors briefly report on their work recently published in Molecular Metabolism.

Watch the most recent interview by clicking the video still. The link "referring article" directs you to this author's publication.



Andrea Rozo, Doris Stoffers
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA
Referring article

Other Scientists...
Issue Alert
If you want to be alerted via email when new content that matches your interests is available, please login or register at www.molmetab.com/user/alerts
Conferences & Events
September
17 − 19
2017
5th Helmholtz-Nature Medicine Diabetes Conference
Munich, Germany
October
1 − 5
2017
Lifetime Influence of Genes and Environment
Copenhagen, Denmark
October
15 − 17
2017
Cell Symposia: Metabolic Disease Therapies
San Diego, USA
Supported by